2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12G.02 Real-World Biomarker Testing and Treatment Patterns for Locally Advanced and Metastatic Non-Small Cell Lung Cancer in Canada

EP.12G.02 Real-World Biomarker Testing and Treatment Patterns for Locally Advanced and Metastatic Non-Small Cell Lung Cancer in Canada

Back to course

Pdf Summary

The study explores real-world biomarker testing and treatment patterns for locally advanced/metastatic non-small cell lung cancer (NSCLC) in Canada, highlighting key data on the prevalence of advanced treatments and the necessity for comprehensive biomarker testing. NSCLC accounts for 80-85% of new lung cancer cases, and recent treatment advancements target actionable genomic alterations (AGAs). However, not all patients receive full AGA testing, particularly in community settings, which underscores the need for better access to these tests.<br /><br />The observational study included data from 205 patients using IQVIA’s Oncology Patient Outcomes platform, focusing on those diagnosed between January 2018 and April 2023. Notable findings indicate that even though a considerable portion of patients (93.6%) were tested for at least one AGA, only 36.0% were tested comprehensively for all known AGAs. EGFR mutations had the highest detection rates, and the testing rates were notably higher in academic centers compared to community settings.<br /><br />Treatment patterns showed a shift from chemotherapy-only regimens to those incorporating immunotherapy, with an increased deployment of immune checkpoint inhibitors (ICI) from 2018-2019 to 2022-2023. Despite this progress, only 69.0% of patients with AGAs received targeted therapies by the second line (2L) treatment, while the majority of those without AGAs received ICI-linked chemotherapy in their first line (1L) treatment.<br /><br />This data reveals an unmet need for aligning clinical practice with guideline-recommended therapies for NSCLC in Canada. The study, however, is limited by potential selection bias due to data collected from a small fraction of oncologists, suggesting the need for future validation using larger datasets. The study highlights the necessity for enhancing biomarker testing access and integrating emerging treatment modalities into routine care.

Asset Subtitle

Rana Qadeer

Meta Tag

Speaker Rana Qadeer

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

NSCLC

biomarker testing

Canada

genomic alterations

EGFR mutations

immunotherapy

immune checkpoint inhibitors

targeted therapies

treatment patterns

clinical practice